ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending

Reuters

2025/11/12

ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending

ProMIS Neurosciences Inc. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582006373"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582006373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582006373?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582006373","market":"nz","top_or_hot":-1,"title":"ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMN","symbol_name":"ProMIS Neurosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL4cqxzN:1","article_id":"2582006373","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582006373","pubTimestamp":1762949131,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProMIS Neurosciences Inc. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMN":"ProMIS Neurosciences Inc","BK4139":"生物科技"},"translate_title":"ProMIS Neurosciences因临床试验支出增加而第三季度亏损1180万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMN":0.9},"content_text":"ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending\n    \n\nProMIS Neurosciences Inc. reported financial results for the third quarter ended September 30, 2025. Research and development expenses increased to $9.8 million for the quarter, compared to $2.6 million in the same period of 2024. For the nine months ended September 30, 2025, research and development expenses were $24.0 million, up from $6.3 million in the prior year period. The accumulated deficit as of September 30, 2025, was $119.7 million, compared to $90.7 million as of September 30, 2024. Total shareholders' equity was $9.2 million, down from $16.5 million in the previous year. During the period, ProMIS focused on advancing its PRECISE-AD trial for its first clinical candidate, PMN310, and strengthened its board with the addition of Slanix Paul Alex, Pharm.D. The company also raised additional capital to support its strategic and clinical goals.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}